Tumor sphericity predicts response in neoadjuvant chemotherapy for invasive breast cancer

12Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

This retrospective study examined magnetic resonance imaging (MRI)–derived tumor sphericity (SPH) as a quantitative measure of breast tumor morphology, and investigated the association between SPH and reader-assessed morphological pattern (MP). In addition, association of SPH with pathologic complete response was evaluated in patients enrolled in an adaptively randomized clinical trial designed to rapidly identify new agents for breast cancer. All patients underwent MRI examinations at multiple time points during the treatment. SPH values from pretreatment (T0) and early-treatment (T1) were investigated in this study. MP on T0 dynamic contrast-enhanced MRI was ranked from 1 to 5 in 220 patients. Mean SPH values decreased with the increased order of MP. SPH was higher in patients with pathologic complete response than in patients without (difference at T0: 0.04, 95% confidence interval [CI]: 0.02–0.05, P

Cite

CITATION STYLE

APA

Li, W., Newitt, D. C., Yun, B. L., Jones, E. F., Arasu, V., Wilmes, L. J., … Hylton, N. M. (2020). Tumor sphericity predicts response in neoadjuvant chemotherapy for invasive breast cancer. Tomography, 6(2), 216–222. https://doi.org/10.18383/j.tom.2020.00016

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free